A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Subcutaneously Administered Teplizumab (MGA031) in Adults With Type 1 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2015
At a glance
- Drugs Teplizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms SUBCUE
- Sponsors MacroGenics
- 22 Oct 2010 Status changed from recruiting to suspended.
- 07 Sep 2010 New trial record